Patents by Inventor Chung-Ming Hsieh

Chung-Ming Hsieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20160347850
    Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: Lorenzo Benatuil, Bradford L. McRae, Maria A. Argiriadi, Chung-Ming Hsieh
  • Anti-EGFR antibodies and antibody drug conjugates
    Patent number: 9493568
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: November 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • IL-17 binding proteins
    Patent number: 9481736
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: November 1, 2016
    Assignee: AbbVie, Inc.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • IL-17 binding proteins
    Patent number: 9481735
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: November 1, 2016
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • Therapeutic DLL4 binding proteins
    Patent number: 9469689
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: October 18, 2016
    Assignee: AbbVie Inc.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jijie Gu, Susan E. Morgan-Lappe, Yingchun Li
  • Therapeutic DLL4 binding proteins
    Patent number: 9469688
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: October 18, 2016
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Single chain multivalent binding protein compositions and methods
    Patent number: 9458244
    Abstract: Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: October 4, 2016
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Chung-Ming Hsieh
  • TNF-ALPHA BINDING PROTEINS
    Publication number: 20160272703
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Application
    Filed: February 15, 2016
    Publication date: September 22, 2016
    Inventors: Chung-ming HSIEH, Carrie GOODREAU, Tariq GHAYUR, Achim MOELLER, Sahana BOSE
  • IL-1 binding proteins
    Patent number: 9447184
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: September 20, 2016
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • IL-1 binding proteins
    Patent number: 9447183
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: September 20, 2016
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • IL-1 binding proteins
    Patent number: 9441038
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: September 13, 2016
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • IL-1 binding proteins
    Patent number: 9409986
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: August 9, 2016
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
    Patent number: 9394363
    Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ? and advanced glycation-end-products.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: July 19, 2016
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Jijie Gu, Chung-Ming Hsieh, Zhen Wu, Enrico L. DiGiammarino, Feng Luo, Gerard B. Fox, John E. Harlan, Martin Schmidt, Ralf Loebbert, Reinhold Mueller, Ulrich Ebert, Volker Nimmrich
  • METHODS FOR TRANSFORMING YEAST
    Publication number: 20160153001
    Abstract: This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.
    Type: Application
    Filed: October 28, 2015
    Publication date: June 2, 2016
    Inventors: Chung-ming Hsieh, Jonathan P. Belk, Jennifer M. Perez, Lorenzo Benatuil
  • IL-1 binding proteins
    Patent number: 9303085
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: April 5, 2016
    Assignee: ABBVIE INC.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • THERAPEUTIC DLL4 BINDING PROTEINS
    Publication number: 20160060332
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Application
    Filed: August 10, 2015
    Publication date: March 3, 2016
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Therapeutic DLL4 Binding Proteins
    Publication number: 20160031986
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Application
    Filed: July 14, 2015
    Publication date: February 4, 2016
    Inventors: Ming-Jiu CHEN, Chung-Ming HSIEH, Jijie GU, Susan E. MORGAN-LAPPE, Yingchun LI
  • AMYLOID-BETA BINDING PROTEINS
    Publication number: 20150368299
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any ? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Application
    Filed: June 22, 2015
    Publication date: December 24, 2015
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Chung-Ming Hsieh
  • DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-13 AND/OR IL-17
    Publication number: 20150344566
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: July 21, 2015
    Publication date: December 3, 2015
    Inventors: Chung-Ming HSIEH, Tariq GHAYUR, Carrie L. GOODREAU
  • Methods for transforming yeast
    Patent number: 9200270
    Abstract: This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: December 1, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-ming Hsieh, Jonathan P. Belk, Jennifer M. Perez, Lorenzo Benatuil